Drug Type Small molecule drug |
Synonyms Encequidar/irinotecan, Irinotecan/HM 30181A, Irinotecan/HM30181AK + [3] |
Target |
Mechanism P-gp inhibitors(P-glycoprotein 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H45ClN4O9 |
InChIKeyKLEAIHJJLUAXIQ-JDRGBKBRSA-N |
CAS Registry136572-09-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Phase 1 | KR | 18 May 2020 | |
Breast Cancer | Phase 1 | CN | 29 Apr 2019 | |
Solid tumor | Preclinical | US | 05 Sep 2014 | |
Advanced cancer | Preclinical | KR | 01 Dec 2010 | |
Advanced Malignant Solid Neoplasm | Preclinical | KR | 01 Jun 2008 |
Phase 1 | 21 | (Capecitabine 800mg/㎡ + Oratecan 10mg/㎡) | ljwarnslkm(nmnwzhgjkd) = pcbbhxvycb ldctzubwaw (onvpbkiyem, canlcuraiu - fglhgjsubb) View more | - | 23 Apr 2015 | ||
(Capecitabine 800mg/㎡ + Oratecan 15mg/㎡) | ljwarnslkm(nmnwzhgjkd) = cimhyhanls ldctzubwaw (onvpbkiyem, nqpkcvkyjo - hyiezywjfk) View more |